Voronoi, Signed Contract for Technology Transfer in Targeted Therapy Research and Development

[Asia Economy Reporter Lee Jung-yoon] Voronoi announced on the 22nd that it has signed a technology licensing agreement with Voronoi Bio for the research and development of a new targeted therapy.

The company stated, "The technology involves a targeted therapy candidate substance aimed at mutations in EGFR non-small cell lung cancer," adding, "It is planned to be developed as an oral drug with higher mutation selectivity and brain permeability compared to competing substances."